All In MedTech

Device Trial Radar · NCT03319160

LifeVest Safety and Efficacy in Real Life Settings in France

Post-market Clinical Follow-up Study Evaluating the Efficacy and Safety of LifeVest in Real-life Settings in France

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,164

Actual

Start

Feb 2, 2017

Primary completion

Sep 30, 2018

Study completion Mar 30, 2019

Sponsor

Lead sponsor
Zoll Medical CorporationNot on our public-company list
Sponsor type
Industry
First posted
Oct 24, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This post-market study is a prospective observational study evaluating the efficacy and safety of the LifeVest in real-life settings.

Conditions

  • Sudden Cardiac Death
  • Left Ventricular Dysfunction
  • Cardiac Event
  • Cardiac Arrythmias

Interventions

  • Wearable Cardioverter DefibrillatorDevice

    A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Appropriate Shock Events Per PatientTime frame: start to end of WCD use (3 months typical prescription)
  2. Risk of Not Receiving Appropriate Shocks When NecessaryTime frame: from start to end of WCD use (3 months typical prescription)
  3. Inappropriate Shock Events Per PatientTime frame: from start to end of WCD use (3 months typical prescription)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Clinique PASTEUR

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.